Guben Qushi Granule for Allergic Asthma: A Randomazied Double-blinded Placebo-controlled Pilot Study and its Therapeutic Mechanism

Status

Active, not recruiting

Phases

Early Phase 1

Study type

Interventional

Source

ITMCTR

Registry ID

ITMCTR2200006677

Enrollment

Unknown

Registered

2022-10-02

Start date

2022-10-01

Completion date

Unknown

Last updated

2023-02-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Allergic Asthma

Interventions

Control group:Guben Qushi Placebo Granule

Experimental group:Guben Qushi Granule

Eligibility

Sex/Gender

All

Age

18 Years to 75 Years

Inclusion criteria

Inclusion criteria: ?Patients who are aged 18–75 years; ?Patients who meet the diagnostic criteria of allergic asthma, with the chronic persistent stage, diagnosed with mild to moderate stage; ?ACT score is Less than or equal to 19 points; ?Patients who meet the Chinese medicine syndrome classification of Qi deficiency and dampness obstruction; ?Patients who sign the informed consent form.

Exclusion criteria

Exclusion criteria: ?Patients with severe asthma; ?Patients with acute severe or critical asthma in recent 1 month; ?Patients with chronic obstructive pulmonary disease, bronchiectasis, interstitial lung disease, active tuberculosis or other respiratory diseases; ?Patients with severe or uncontrollable basic disease: liver dysfunction (ALT or AST >= 3ULN, total bilirubin >= 1.5ULN), renal dysfunction (serum creatinine > 177µmol/L or 2mg/dl), congestive heart failure (III-IV); immune deficiency, tumor, organ or bone marrow transplantation, HIV or immunosuppressive therapy in recent 3 months; ?Patients with poor acception for intervention or mental disesese; ?Patient cannot complete the lung function test; ?Patient with history of allergies or hypersensitivity for any research drug component; ?Patients who are pregnant or lactating; ?Patients have accepted or accepting allergen specific immunotherapy or anti IgE; ?Patients who Participated in or plan to participate in other clinical trials

Design outcomes

Primary

Measure	Time frame
ACT score;	—

Secondary

Measure	Time frame
ACQ questionnaire;Changes of FeNO;Blood EOS;Frequency;the Dampness Syndrome Scale of Chinese Medicine;Changes of pulmonary function parameters;Asthma symptom score;Sputum EOS%;AQLQ questionnaire;	—

Countries

China

Contacts

Public ContactLin Lin

drlinlin620@163.com81887233-38605

Outcome results

None listed

Source: ITMCTR (via WHO ICTRP) · Data processed: Feb 4, 2026